Please login to the form below

Not currently logged in
Email:
Password:

Biomarkers predict rheumatoid drug success

Remission is more likely for RA patients with positive rheumatoid factor or aCCP over seronegative patients after MabThera plus MTX treatment

Rheumatoid arthritis (RA) patients who test positive for the auto-antibodies rheumatoid factor (RF) or anti-cyclic citrullinated peptide (aCCP) are more than twice as likely to achieve remission and are three times more likely to get a significant improvement in symptoms when taking MabThera (rituximab) plus methotrexate (MTX) than those who test negative, according to new research presented at the British Society of Rheumatology (BSR) annual conference.

The research consisted of two phase III studies led by Professor John Isaacs, professor of clinical rheumatology at Newcastle University, and involved eight centres in which patients with active RA who had previously experienced an inadequate response to other disease-modifying anti-rheumatic drugs (DMARDs) were treated with the monoclonal antibody rituximab plus MTX. A total of 670 patients (554 seropositive and 116 seronegative) were pooled and analysed.

At week 48, 44.9 per cent of seropositive patients achieved a 50 per cent reduction in the signs and symptoms of RA, compared with the 22.8 per cent of seronegative patients who achieved the same degree of improvement.

Professor John Isaacs commented: "By identifying in advance which groups are most likely to respond to, or to have an enhanced response to, drugs like rituximab, we can ensure they are treated early enough to prevent irreversible joint damage and disability. Additionally this will reduce treatment costs by avoiding the use of ineffective drugs."

This constitutes the first time research into the treatment of RA has been able to identify biomarkers to pinpoint which patients would respond better to any specific treatment. Approximately 80 per cent of patients with RA are seropositive for one of these auto-antibodies. The economic burden of RA is currently estimated at almost £8bn annually.

21st April 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics